174 related articles for article (PubMed ID: 35895805)
1. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D
Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805
[TBL] [Abstract][Full Text] [Related]
2. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
3. Targeting Glutamine Metabolism through Glutaminase Inhibition Suppresses Cell Proliferation and Progression in Nasopharyngeal Carcinoma.
Su C; Li M; Yang Y; Wang Z; Wang Q; Wang W; Ma X; Jie R; Chen H; Li X; Lu J
Anticancer Agents Med Chem; 2023; 23(17):1944-1957. PubMed ID: 37497684
[TBL] [Abstract][Full Text] [Related]
4. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Liu J; Zhang C; Lin M; Zhu W; Liang Y; Hong X; Zhao Y; Young KH; Hu W; Feng Z
Oncotarget; 2014 May; 5(9):2635-47. PubMed ID: 24797434
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis reveals that SLC38A1 promotes hepatocellular carcinoma development via PI3K/AKT/mTOR signaling via glutamine mediated energy metabolism.
Feng HG; Wu CX; Zhong GC; Gong JP; Miao CM; Xiong B
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15879-15898. PubMed ID: 37673823
[TBL] [Abstract][Full Text] [Related]
6. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J
Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856
[TBL] [Abstract][Full Text] [Related]
7. Low expression of
Liang Q; Liu S; Yin F; Liu M; Wang L; Guo E; Lei L; Wu L; Yang Y; Zhang D; Zeng X
Biomark Med; 2023 Sep; 17(18):755-765. PubMed ID: 38095985
[No Abstract] [Full Text] [Related]
8. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial ribosomal protein L12 potentiates hepatocellular carcinoma by regulating mitochondrial biogenesis and metabolic reprogramming.
Ji X; Yang Z; Li C; Zhu S; Zhang Y; Xue F; Sun S; Fu T; Ding C; Liu Y; Wan Q
Metabolism; 2024 Mar; 152():155761. PubMed ID: 38104924
[TBL] [Abstract][Full Text] [Related]
10. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
11. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
[TBL] [Abstract][Full Text] [Related]
12. LncRNA RHPN1-AS1 Promotes Cell Proliferation, Migration and Invasion Through Targeting miR-7-5p and Activating PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma.
Song XZ; Ren XN; Xu XJ; Ruan XX; Wang YL; Yao TT
Technol Cancer Res Treat; 2020; 19():1533033820957023. PubMed ID: 32910747
[TBL] [Abstract][Full Text] [Related]
13. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
[TBL] [Abstract][Full Text] [Related]
14. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
15. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma.
Bai J; Tang R; Zhou K; Chang J; Wang H; Zhang Q; Shi J; Sun C
BMC Med Genomics; 2022 Oct; 15(1):222. PubMed ID: 36284275
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
[TBL] [Abstract][Full Text] [Related]
17. SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway.
Wang H; Chen M; Yang C; Hu H; Jiang Y; Yang F; Lv L
Arch Biochem Biophys; 2023 Jul; 743():109661. PubMed ID: 37268273
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
[TBL] [Abstract][Full Text] [Related]
19. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
20. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
